ArticleJournal of ovarian research2026
Dynamic changes in homologous recombination status before and after chemotherapy in advanced ovarian, fallopian tube, and primary peritoneal cancers.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Clinically Translatable Multimodal Deep Learning Model for HRD Detection from Histopathology Images.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHomologous recombination (HR) status plays a pivotal role in the management of advanced ovarian cancers, particularly in guiding the use of PARP inhibitors. In patients receiving neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS), tumor samples are available both before and after chemotherapy. This study evaluated the impact of NAC on HR status using paired pre- and post-NAC samples.
methodsBetween 2020 and 2023, 128 patients with ovarian cancer were treated at our institution; 24 underwent NAC followed by IDS. Genomic instability scores (GIS) and tumor BRCA (tBRCA) mutation status were assessed using the Myriad myChoice® assay. Paired analyses included cases with both pre- and post-NAC samples.
resultsPost-NAC HR assessment was unavailable in 8 of 24 patients (33%) due to insufficient or degraded tumor tissue. Paired HR status evaluation was therefore feasible in 15 patients. Among these paired evaluable cases, tBRCA mutation status remained unchanged. GIS scores significantly decreased in HR-deficient (HRD) tumors, whereas no significant change was observed in HR-proficient (HRP) tumors. The median ΔGIS was − 6, indicating a reduction after NAC. Two patients converted from HRD to HRP status after NAC, crossing the HRD threshold of 42.
conclusionsOur findings suggest that NAC may reduce GIS and alter HR status in HRD tumors. Limited tissue availability after NAC poses a practical challenge for HR assessment, and HRD-to-HRP conversion may affect eligibility for HR-targeted therapies. These findings support performing HRD testing prior to chemotherapy whenever feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.